<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539639</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK011</org_study_id>
    <nct_id>NCT04539639</nct_id>
  </id_info>
  <brief_title>Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis</brief_title>
  <acronym>AD</acronym>
  <official_title>A Multi-center,Randomized,Double-blind,Placebo,Parallel-controlled Phase II Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants&#xD;
      with moderate to severe atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into two stages, the first stage test (1-12 weeks): the main test; the&#xD;
      second stage test (13-24 weeks): the extended test.&#xD;
&#xD;
      The main test：The trial set up 4 treatment groups, including 3 dose exploration groups,&#xD;
      Jaktinib 50mg Bid, 75mg Bid, 100mg Bid group and 1 placebo control group.&#xD;
&#xD;
      The extended test：Subjects in the placebo group were randomly assigned to receive Jaktinib&#xD;
      50mg Bid, 75mg Bid, and 100mg Bid treatments at a ratio of 1:1:1 (randomized in a blinded&#xD;
      state and completed by IWRS in the background), the main test group (50mg Bid, 75mg Bid,&#xD;
      100mg Bid group) subjects still maintain the original dose after 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving at least a 50% Reduction in Eczema Area and Severity Index (EASI 50) from Baseline</measure>
    <time_frame>At Week 12</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving IGA of 0 or 1.</measure>
    <time_frame>Treatment at 2,4,8,12,16,20,24 weeks</time_frame>
    <description>The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 with a ≥2 Point Improvement</measure>
    <time_frame>Treatment at 2,4,8,12,16,20,24 weeks</time_frame>
    <description>The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">161</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Jaktinib 50mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib 50mg Bid+ Placebo 50mg Bid+Placebo 75mg Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib 75mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib 75mg Bid+ Placebo 100mg Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib 100mg Bid+ Placebo 75mg Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 100mg Bid+ Placebo 75mg Bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jacketinib</intervention_name>
    <description>In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.</description>
    <arm_group_label>Jaktinib 50mg Bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jacketinib</intervention_name>
    <description>In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.</description>
    <arm_group_label>Jaktinib 75mg Bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jacketinib</intervention_name>
    <description>In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.</description>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the Chinese diagnostic criteria for atopic dermatitis (Zhang's criteria) and be&#xD;
             diagnosed as atopic dermatitis.&#xD;
&#xD;
          -  Participants must have moderate to severe AD at screening and randomization.&#xD;
&#xD;
          -  Participants must have inadequate response to topical medications within 6 months of&#xD;
             screening.&#xD;
&#xD;
          -  Agree to use emollients daily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Have received certain types of vaccinations.&#xD;
&#xD;
          -  Participants who do not agree to use adequate contraception during the trial and&#xD;
             within 4 weeks after the last dose.&#xD;
&#xD;
          -  Any Participants whom the investigator deems inappropriate for participation in this&#xD;
             clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qianjin Lu</last_name>
    <role>Study Chair</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianjin Lu, PhD</last_name>
    <phone>+8673185295999</phone>
    <email>Qianlu5860@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianzhong Zhang, phD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>139 People's Middle Road</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianjin M Road</last_name>
      <phone>+8673185295999</phone>
      <email>Qianlu5860@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Qianjin Lu, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianzhong Zhang, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

